Дискуссионные представления о двусмысленности медицины

Автор: Муравьев Ю.В., Муравьева Л.А.

Журнал: Научно-практическая ревматология @journal-rsp

Рубрика: Дискуссия

Статья в выпуске: 5 т.55, 2017 года.

Бесплатный доступ

Обсуждаются дискуссионные представления о возможных причинах неопределенности в медицине, возникшей в эпоху цифровых технологий и информационного наводнения.

Цифровые технологии, рандомизированные клинические испытания, неблагоприятные реакции, олигополия, генно-инженерные биологические препараты

Короткий адрес: https://readera.org/14945866

IDR: 14945866   |   DOI: 10.14412/1995-4484-2017-580-581

Список литературы Дискуссионные представления о двусмысленности медицины

  • Unnikrishnan MK. Eminence or Evidence? The Volatility, Uncertainty, Complexity, and Ambiguity in Healthcare. J Pharmacol Pharmacother. 2017; 8(1): 1-2 DOI: 10.4103/jppJPP_12_17
  • Golder S, Loke YK, Wright K, Norman G. Reporting of adverse events in published and unpublished studies of health care interventions: A systematic review. PLoS Med. 2016; 13: e1002127.
  • Lundh A, Sismondo S, Lexchin J, et al. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2012; 12: MR000033 DOI: 10.1002/14651858.MR000033.pub2
  • ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002; 288(23): 2998-3007 DOI: 10.1001/jama.288.23.2998
  • Han BH, Sutin D, Williamson JD, et al. Effect of statin treatment vs usual careon primary cardiovascular prevention among older adults the ALLHAT-LLT randomized clinical trial. JAMA Intern Med. 2017 May 22 DOI: 10.1001/jamainternmed.2017.1442
  • Abramson JD, Rosenberg HG, Jewell N, Wright JM. Should people at low risk of cardiovascular disease take a statin? BMJ. 2013; 347: f6123 DOI: 10.1136/bmj.f6123
  • Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016; 388: 2532-61 DOI: 10.1016/S0140-6736(16)31357-5
  • Heath I, Evans S, Furberg C, et al. Report of the independent panel considering the retraction of two articles in the BMJ. BMJ. 2014; 349: g5176 DOI: 10.1136/bmj.g5176
  • Holleman F, Uijldert M, Donswijk LF, Gale EA. Productivity of authors in the field of diabetes: Bibliographic analysis of trial publications. BMJ. 2015; 351: h2638 DOI: 10.1136/bmj.h2638
  • Zink A, Strangfeld A, Schneider M, et al. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum. 2006; 54: 3399-407 DOI: 10.1002/art.22193
  • Aaltonen KJ, Ylikylä S, Tuulikki Joensuu J, et al. Efficacy and effectiveness of tumour necrosis factor inhibitors in the treatment of rheumatoid arthritis in randomized controlled trials and routine clinical practice. Rheumatology (Oxford). 2017; 56(5): 725-35.
Еще
Статья научная